Teva Pharmaceuticals
TEVA
438 hedge funds and large institutions have $4.95B invested in Teva Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 64 funds opening new positions, 115 increasing their positions, 147 reducing their positions, and 40 closing their positions.
60% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 40
4% more funds holding
Funds holding: 422 → 438 (+16)
0.12% less ownership
Funds ownership: 50.56% → 50.44% (-0.12%)
2% less capital invested
Capital invested by funds: $5.05B → $4.95B (-$97.7M)
8% less funds holding in top 10
Funds holding in top 10: 12 → 11 (-1)
13% less call options, than puts
Call options by funds: $231M | Put options by funds: $265M
22% less repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 147
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
Ion Asset Management
Herzliya,
Israel
|
+$227M |
| 2 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$80.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$68M |
| 4 |
Millennium Management
New York
|
+$51M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$44.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$318M |
| 2 |
ACM
Abrams Capital Management
Boston,
Massachusetts
|
-$78.8M |
| 3 |
Legal & General Group
London,
United Kingdom
|
-$62.5M |
| 4 |
BCP
BSN Capital Partners
London,
United Kingdom
|
-$50.7M |
| 5 |
Two Sigma Investments
New York
|
-$43.6M |
TEVA Hedge Fund Activity: Q1 2023 in Review
438 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q1 2023, worth a combined $4.95B — down 1.9% from $5.05B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new TEVA positions and 40 closed out — a net gain of 24 holders — while 115 added to existing stakes and 147 trimmed.
The largest buyer was Ion Asset Management, adding an estimated $227M. The largest seller was Capital Research Global Investors, cutting an estimated $318M.
- 438 institutional investors held Teva Pharmaceuticals (TEVA) as of Q1 2023, up from 422 in Q4 2022.
- Funds reported $4.95B of Teva Pharmaceuticals stock for Q1 2023, down 1.9% quarter-over-quarter.
- 64 funds opened new Teva Pharmaceuticals positions in Q1 2023 and 40 closed out, a net change of +24 holders.
- The largest Teva Pharmaceuticals buyer in Q1 2023 was Ion Asset Management, an estimated $227M added.
- The largest Teva Pharmaceuticals seller in Q1 2023 was Capital Research Global Investors, an estimated $318M sold.
Based on aggregated 13F filings for Q1 2023.